CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the closing of its previously announced underwritten public offering of 14,270,074 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,861,314 shares, at the public offering price of $6.85 per share.

马萨诸塞州剑桥-（BUSINESS WIRE）-Scholar Rock Holding Corporation（纳斯达克股票代码：SRRK）是一家专注于治疗蛋白质生长因子发挥重要作用的严重疾病的3期临床阶段生物制药公司，今天宣布关闭其先前宣布的承保公开发行14270074股普通股，其中包括承销商完全行使其选择购买额外1861314股股份的权利，公开发行价格为每股6.85美元。

Gross proceeds to Scholar Rock in the offering, before underwriting discounts and estimated expenses of the offering, were approximately $97.8 million..

在承保折扣和提供的估计费用之前，提供给Scholar Rock的总收益约为9780万美元。。

J.P. Morgan Securities LLC and Piper Sandler & Co. acted as joint book-running managers for the offering. BMO Capital Markets Corp. and Wedbush Securities Inc. acted as co-managers for the offering.

J、 P.Morgan Securities LLC和Piper Sandler＆Co.担任该产品的联合图书运营经理。BMO资本市场公司和Wedbush证券公司担任该产品的联合经理。

The securities described above are being offered by Scholar Rock pursuant to a shelf registration statement on Form S-3 (No. 333-268329) that was declared effective by the Securities and Exchange Commission (SEC) on November 25, 2022. A prospectus supplement describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov.

上述证券由Scholar Rock根据美国证券交易委员会（SEC）于2022年11月25日宣布生效的表格S-3（第333-268329号）的货架注册声明提供。描述产品条款的IPO补充资料已向SEC提交，并可在位于www.SEC.gov的SEC网站上查阅。

A copy of the final prospectus supplement and accompanying prospectus relating to the securities may also be obtained, by contacting: J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at 800-747-3924 or by email at prospectus@psc.com..

还可以通过以下方式获得最终承销说明书补充和随附的与证券有关的承销说明书的副本：J.P.Morgan securities LLC，c/o:Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，电话：866-803-9204或通过电子邮件：prospectus-eq_fi@jpmchase.com; 或Piper-Sandler＆Co.，800 Nicollet Mall，J12S03，Minneapolis，MN 55402，注意：IPO部门，电话800-747-3924或电子邮件地址：prospectus@psc.com..

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction..

本新闻稿不构成出售或征求购买这些证券的报价，也不构成在注册前在任何州或管辖区销售这些证券的非法行为或根据该州或管辖区证券法的资格。。

About Scholar Rock

关于学者岩石

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.

Scholar Rock是一家临床阶段的生物制药公司，专注于发现和开发用于治疗严重疾病的创新药物，其中蛋白质生长因子的信号传导起着重要作用。Scholar Rock正在创建一系列新产品候选人，有可能改变患有各种严重疾病（包括神经肌肉疾病，癌症和纤维化）的患者的生活。

Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect.

Scholar Rock针对生长因子激活分子机制的方法使其能够开发一个专有平台，用于发现和开发在细胞水平上局部和选择性靶向这些信号蛋白的单克隆抗体。通过开发在疾病微环境中起作用的候选产品，该公司打算避免与抑制生长因子的治疗效果相关的历史挑战。

Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path..

Scholar Rock认为，它关注生物学验证的生长因子可能有助于更有效的发展道路。。

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

ScholarRock®是Scholar Rock，Inc.的注册商标。